Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a Two-Drug cocktail tame ALS? early trial hints at hope

NCT ID NCT06307301

Completed Disease control Sponsor: The Methodist Hospital Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested whether combining two drugs—abatacept and interleukin-2—is safe for people with ALS. The goal was to boost the body's regulatory T cells, which may help slow disease progression. Only 5 participants were enrolled, and the study focused on safety and immune system changes, not on curing the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
abatacept (Orencia) and interleukin-2 (aldesleukin)
What this could lead to
If safe and effective, this combination could help slow ALS progression by boosting the body's own immune regulation.
What could go wrong
This is a very early, small phase 1 trial with only 5 participants, so results may not apply to all ALS patients. Side effects from the drugs are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

amyotrophic lateral sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AMYOTROPHIC LATERAL SCLEROSIS

Contacts and locations

Locations

  • Houston Methodist Research Institute

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.